Byung Kyu Lee

Title: Byung Kyu Lee: Innovator in Humanized Antibody Development

Introduction

Byung Kyu Lee is a prominent inventor based in Gunpo-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 2 patents, his work focuses on innovative solutions for treating various diseases.

Latest Patents

One of his latest patents is a humanized antibody specific for tumor necrosis factor-alpha. This invention involves preparing humanized antibodies from a mouse monoclonal antibody using the CDR grafting method. These antibodies exhibit an antigen binding affinity similar to the original mouse monoclonal antibody while demonstrating significantly low immunogenicity. As a result, they can be effectively utilized for treating diseases related to hTNF-α, including rheumatoid arthritis, Crohn's disease, and asthma.

Another notable patent is a humanized antibody against the S-surface antigen of the hepatitis B virus. This invention shows similar antigen-binding affinity to a mouse monoclonal antibody and significantly low immunogenicity. Consequently, it can be effectively used for treating chronic hepatitis B and preventing HBV infection in patients undergoing liver transplantation.

Career Highlights

Byung Kyu Lee is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has been instrumental in advancing therapeutic options for patients suffering from various conditions.

Collaborations

He has collaborated with notable colleagues, including Tae Hyoung Yoo and Moo Young Song, to further enhance the research and development of innovative medical solutions.

Conclusion

Byung Kyu Lee's contributions to the field of biotechnology, particularly in humanized antibody development, highlight his role as a key innovator. His patents reflect a commitment to improving treatment options for patients with serious health conditions.